Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 6.

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.

Author information

  • 1University of Virginia School of Medicine, Charlottesville, VA, USA. mew4p@virginia.edu

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination. Although MCL is incurable with current therapies, with the exception of allogeneic stem cell transplant, recent advances are improving long-term outcomes in MCL. Intensive research has continued to focus on elucidating biological mechanisms of MCL, identifying new molecular targets, and optimizing existing therapies. Most recently, researchers have begun focusing on new areas such as epigenetics and microRNAs and their potential applications to MCL therapy. Advances across a broad spectrum of MCL research were presented at a recent MCL Workshop. This report provides an overview of the scientific highlights from the meeting and a framework for future research.

PMID:
21133727
DOI:
10.3109/10428194.2010.532893
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center